SLNO RSI Chart
Last 7 days
2.6%
Last 30 days
21.8%
Last 90 days
-2.4%
Trailing 12 Months
955.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2017 | 0 | 0 | 0 | 0 |
2016 | 812.6K | 1.0M | 1.2M | 1.5M |
2015 | 2.3M | 1.7M | 1.0M | 387.6K |
2013 | 0 | 0 | 0 | 3.0M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 30, 2024 | vivo opportunity, llc | sold | -15,851,600 | 45.13 | -351,242 | - |
Apr 29, 2024 | vivo opportunity, llc | sold | -35,850,000 | 47.8 | -750,000 | - |
Apr 01, 2024 | anish bhatnagar | sold | -784,645 | 41.3406 | -18,980 | chief executive officer |
Apr 01, 2024 | yen kristen | sold | -91,693 | 41.3407 | -2,218 | see remarks |
Apr 01, 2024 | mackaness james h | sold | -213,937 | 41.3406 | -5,175 | chief financial officer |
Apr 01, 2024 | hirano patricia c | sold | -91,693 | 41.3407 | -2,218 | see remarks |
Jan 25, 2024 | yen kristen | sold | -19,175 | 48.3 | -397 | see remarks |
Jan 25, 2024 | hirano patricia c | sold | -40,185 | 48.3 | -832 | see remarks |
Jan 25, 2024 | anish bhatnagar | sold | -122,054 | 48.3 | -2,527 | chief executive officer |
Jan 08, 2024 | mario ernest | gifted | - | - | -3,523 | - |
Which funds bought or sold SLNO recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 17, 2024 | Ikarian Capital, LLC | reduced | -4.21 | 442,310 | 24,199,600 | 2.65% |
May 16, 2024 | JANE STREET GROUP, LLC | reduced | -67.36 | -1,194,540 | 635,066 | -% |
May 16, 2024 | AWM Investment Company, Inc. | sold off | -100 | -805,000 | - | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | added | 33.8 | 175,249 | 589,784 | -% |
May 15, 2024 | Ghost Tree Capital, LLC | added | 77.96 | 4,036,500 | 8,560,000 | 2.37% |
May 15, 2024 | COMMODORE CAPITAL LP | reduced | -87.89 | -49,094,000 | 7,256,010 | 0.48% |
May 15, 2024 | TCG Crossover Management, LLC | new | - | 23,540,000 | 23,540,000 | 1.86% |
May 15, 2024 | Nantahala Capital Management, LLC | reduced | -57.81 | -126,772,000 | 103,164,000 | 5.89% |
May 15, 2024 | SAMLYN CAPITAL, LLC | reduced | -27.45 | -2,776,450 | 9,370,080 | 0.16% |
May 15, 2024 | Ally Bridge Group (NY) LLC | added | 8.56 | 1,926,110 | 14,401,600 | 8.01% |
Unveiling Soleno Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Soleno Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.91 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.68 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.3 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.27 | 14.48 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Soleno Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||
Description | (%) Q/Q | 2017Q3 | 2017Q2 | 2017Q1 | 2016Q4 | 2016Q3 | 2016Q2 | 2016Q1 | 2015Q4 | 2015Q3 | 2015Q2 | 2015Q1 | 2013Q4 | 2013Q3 |
Revenue | -97.0% | 4,000 | 134,500 | 265,000 | 283,788 | 329,000 | 388,000 | 447,000 | 21,555 | 247,000 | 97,000 | - | - | - |
Cost Of Revenue | -100.0% | - | 42,000 | 209,000 | 410,306 | 399,000 | 51,000 | 461,000 | 256,683 | 56,000 | 22,000 | 18,000 | - | - |
Gross Profit | 100.0% | - | -41,000 | 56,000 | 67,982 | -70,000 | -49,000 | -14,000 | -15,211 | 191,000 | 75,000 | 4,000 | - | - |
Interest Expenses | - | - | - | - | - | - | - | - | -1,000 | - | - | 1,000 | - | 571,000 |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -6.6% | 169 | 181 | 64.00 | 31.00 | 20.00 | 26.00 | 32.00 | 37.00 | 43.00 | 36.00 | 43.00 | 49.00 | 57.00 | 65.00 | 72.00 | 79.00 | 32.00 | 38.00 | 29.00 | 34.00 | 39.00 |
Current Assets | -11.8% | 151 | 171 | 54.00 | 20.00 | 9.00 | 16.00 | 21.00 | 25.00 | 30.00 | 22.00 | 29.00 | 35.00 | 43.00 | 50.00 | 56.00 | 63.00 | 16.00 | 21.00 | 12.00 | 17.00 | 21.00 |
Cash Equivalents | -74.8% | 43.00 | 170 | 52.00 | 19.00 | 8.00 | 15.00 | 20.00 | 24.00 | 29.00 | 21.00 | 28.00 | 34.00 | 42.00 | 49.00 | 56.00 | 62.00 | 15.00 | 21.00 | 11.00 | 16.00 | 19.00 |
Net PPE | 125.0% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities | 9.8% | 25.00 | 23.00 | 40.00 | 19.00 | 17.00 | 16.00 | 17.00 | 17.00 | 16.00 | 18.00 | 22.00 | 21.00 | 19.00 | 19.00 | 24.00 | 23.00 | 23.00 | 23.00 | 14.00 | 20.00 | 15.00 |
Current Liabilities | 17.0% | 13.00 | 12.00 | 29.00 | 9.00 | 8.00 | 7.00 | 7.00 | 7.00 | 7.00 | 8.00 | 9.00 | 8.00 | 10.00 | 9.00 | 8.00 | 8.00 | 7.00 | 5.00 | 3.00 | 3.00 | 2.00 |
Shareholder's Equity | -9.0% | 143 | 158 | 23.00 | 12.00 | 3.00 | 10.00 | 15.00 | 20.00 | 26.00 | 18.00 | 20.00 | 27.00 | 38.00 | 46.00 | 48.00 | 56.00 | 9.00 | 15.00 | 15.00 | 14.00 | 24.00 |
Retained Earnings | -7.7% | -297 | -276 | -265 | -254 | -245 | -237 | -231 | -225 | -219 | -213 | -210 | -202 | -191 | -182 | -179 | -171 | -163 | -157 | -143 | -144 | -134 |
Additional Paid-In Capital | 1.7% | 441 | 434 | 288 | 267 | 248 | 248 | 247 | 246 | 245 | 231 | 231 | 230 | 229 | 228 | 228 | 227 | 173 | 173 | 158 | 158 | 158 |
Accumulated Depreciation | -100.0% | - | 0.00 | - | - | - | 0.00 | - | - | - | 0.00 | - | - | - | 0.00 | - | - | - | 0.00 | - | - | - |
Shares Outstanding | 5.2% | 33.00 | 32.00 | 15.00 | 9.00 | 8.00 | 8.00 | 8.00 | 9.00 | 5.00 | 5.00 | 5.00 | 5.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 33.00 | - | - | - | 8.00 | - | - | - | 61.00 | - | - | - | 98.00 | - | - | - | 28.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -97.2% | -12,500 | -6,340 | -6,306 | -5,594 | -6,700 | -5,143 | -4,656 | -4,620 | -6,362 | -6,863 | -5,406 | -8,013 | -7,488 | -6,867 | -6,164 | -6,534 | -5,659 | -5,076 | -4,719 | -3,893 | -3,687 |
Share Based Compensation | 237.6% | 6,445 | 1,909 | 2,201 | 1,204 | 631 | 632 | 683 | 571 | 644 | 418 | 906 | 857 | 1,095 | 393 | 374 | 341 | 392 | 204 | 153 | 220 | 248 |
Cashflow From Investing | -Infinity% | -115,244 | - | - | - | - | -6.00 | - | - | - | -13.00 | -5.00 | - | -4.00 | -4.00 | - | - | - | 103 | 441 | -6.00 | -10.00 |
Cashflow From Financing | -99.2% | 938 | 123,558 | 39,401 | 17,060 | - | - | 342 | -282 | 14,032 | -5.00 | - | 2.00 | -125 | -42.00 | -195 | 53,963 | -4.00 | - | - | - | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses | ||
Research and development | $ 14,602 | $ 5,316 |
General and administrative | 8,472 | 2,854 |
Change in fair value of contingent consideration | 401 | 299 |
Total operating expenses | 23,475 | 8,469 |
Operating loss | (23,475) | (8,469) |
Other income, net | ||
Interest income, net | 2,077 | 113 |
Total other income, net | 2,077 | 113 |
Net loss | (21,398) | (8,356) |
Other comprehensive income (loss) | ||
Net unrealized loss on marketable securities | (105) | 0 |
Foreign currency translation adjustment | (1) | 16 |
Total comprehensive loss | $ (21,504) | $ (8,340) |
Net loss per common share basic | $ (0.59) | $ (0.88) |
Net loss per common share diluted | $ (0.59) | $ (0.88) |
Weighted-average common shares outstanding used to calculate basic net loss per common share | 36,208,371 | 9,447,350 |
Weighted-average common shares outstanding used to calculate diluted net loss per common share | 36,208,371 | 9,447,350 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 42,847 | $ 169,681 |
Short-term investments | 106,780 | |
Prepaid expenses and other current assets | 1,596 | 1,677 |
Total current assets | 151,223 | 171,358 |
Long-term assets | ||
Property and equipment, net | 27 | 12 |
Operating lease right-of-use assets | 338 | 407 |
Intangible assets, net | 8,263 | 8,749 |
Long-term investments | 8,821 | |
Other long-term assets | 165 | 165 |
Total assets | 168,837 | 180,691 |
Current liabilities | ||
Accounts payable | 8,022 | 3,149 |
Accrued compensation | 1,226 | 3,135 |
Accrued clinical trial site costs | 2,395 | 3,393 |
Operating lease liabilities | 310 | 273 |
Other current liabilities | 1,511 | 1,555 |
Total current liabilities | 13,464 | 11,505 |
Long-term liabilities | ||
Contingent liability for Essentialis purchase price | 11,950 | 11,549 |
Long-term lease liabilities | 37 | 130 |
Total liabilities | 25,451 | 23,184 |
Commitments and contingencies (Note 6) | ||
Stockholders’ equity | ||
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding | ||
Common stock, $0.001 par value, 100,000,000 shares authorized, 33,337,079 and 31,678,159 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 33 | 32 |
Additional paid-in-capital | 441,267 | 433,885 |
Accumulated other comprehensive loss | (106) | |
Accumulated deficit | (297,808) | (276,410) |
Total stockholders’ equity | 143,386 | 157,507 |
Total liabilities and stockholders’ equity | $ 168,837 | $ 180,691 |